Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

EXACT: Randomized Phase II Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC

NCT06863311 is registered in ClinicalTrials.gov with Karie Runcie as lead sponsor.

NCT NCT06863311
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06863311 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
EXACT: Randomized Phase II Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC
Lead sponsor
Karie Runcie
Phase
Phase 2
Overall status
Recruiting
Start date
March 13, 2026
Completion date
December 31, 2028
Enrollment
70 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

advanced renal cell carcinoma, clear cell renal cell carcinoma, metastatic renal cell carcinoma